Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases.
Flawless balance sheet with weak fundamentals.
Share Price & News
How has Anavex Life Sciences's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 12X1's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 12X1 exceeded the German Biotechs industry which returned -13.2% over the past year.
Return vs Market: 12X1 exceeded the German Market which returned -20.9% over the past year.
Price Volatility Vs. Market
How volatile is Anavex Life Sciences's share price compared to the market and industry in the last 5 years?
Simply Wall St News
No news available
Is Anavex Life Sciences undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate 12X1's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate 12X1's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: 12X1 is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.
PE vs Market: 12X1 is unprofitable, so we can't compare its PE Ratio to the German market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 12X1's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 12X1 is overvalued based on its PB Ratio (5.8x) compared to the DE Biotechs industry average (3.3x).
How is Anavex Life Sciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 12X1 is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: 12X1 is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: 12X1 is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: Insufficient data to determine if 12X1's revenue is forecast to grow faster than the German market.
High Growth Revenue: Insufficient data to determine if 12X1's revenue is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 12X1's Return on Equity is forecast to be high in 3 years time
How has Anavex Life Sciences performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 12X1 is currently unprofitable.
Growing Profit Margin: 12X1 is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: 12X1 is unprofitable, and losses have increased over the past 5 years at a rate of -15.9% per year.
Accelerating Growth: Unable to compare 12X1's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 12X1 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.1%).
Return on Equity
High ROE: 12X1 has a negative Return on Equity (-100.03%), as it is currently unprofitable.
How is Anavex Life Sciences's financial position?
Financial Position Analysis
Short Term Liabilities: 12X1's short term assets ($31.4M) exceed its short term liabilities ($5.5M).
Long Term Liabilities: 12X1 has no long term liabilities.
Debt to Equity History and Analysis
Debt Level: 12X1 is debt free.
Reducing Debt: 12X1 has no debt compared to 5 years ago when its debt to equity ratio was 61.2%.
Inventory Level: 12X1 has a low level of unsold assets or inventory.
Debt Coverage by Assets: Insufficient data to determine if 12X1's debt is covered by short term assets.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 12X1 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 12X1 has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of -33% each year.
What is Anavex Life Sciences's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate 12X1's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate 12X1's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if 12X1's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if 12X1's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of 12X1's dividend in 3 years as they are not forecast to pay a notable one for the German market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Chris Missling (53yo)
Dr. Christopher U. Missling, also known as the Chris, MS, Ph.D., MBA. has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and served as its Chief Financial ...
CEO Compensation Analysis
Compensation vs Market: Chris's total compensation ($USD3.38M) is above average for companies of similar size in the German market ($USD744.69K).
Compensation vs Earnings: Chris's compensation has increased whilst the company is unprofitable.
|Principal Financial Officer & Treasurer||4.5yrs||US$224.56k||0.039% $55.8k|
|Chief Operating Officer||2.08yrs||no data||no data|
|Senior Vice President of Regulatory Affairs||no data||no data||no data|
|Chief Medical Officer||no data||no data||no data|
|Executive||no data||no data||no data|
Experienced Management: 12X1's management team is considered experienced (4.5 years average tenure).
|Member of the Scientific Advisory Board||9.08yrs||no data||no data|
|Member of the Scientific Advisory Board||9.17yrs||no data||no data|
|Member of the Scientific Advisory Board||6.33yrs||no data||no data|
|Member of the Scientific Advisory Board||6.42yrs||no data||no data|
|Member of the Scientific Advisory Board||no data||no data||no data|
|Independent Director||5.92yrs||US$93.87k||no data|
|Independent Director||7.25yrs||US$93.87k||2.23% $3.2m|
|Member of the Scientific Advisory Board||5.92yrs||no data||no data|
|Independent Director||2.08yrs||US$109.87k||no data|
Experienced Board: 12X1's board of directors are considered experienced (6.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 12.7%.
Anavex Life Sciences Corp.'s company bio, employee growth, exchange listings and data sources
- Name: Anavex Life Sciences Corp.
- Ticker: 12X1
- Exchange: DB
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$153.702m
- Listing Market Cap: US$142.467m
- Shares outstanding: 58.66m
- Website: https://www.anavex.com
Number of Employees
- Anavex Life Sciences Corp.
- 51 West 52nd Street
- 7th Floor
- New York
- New York
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|AVXL||NasdaqCM (Nasdaq Capital Market)||Yes||Common Shares||US||USD||Apr 2006|
|12X1||DB (Deutsche Boerse AG)||Yes||Common Shares||DE||EUR||Apr 2006|
|0HFR||LSE (London Stock Exchange)||Yes||Common Shares||GB||USD||Apr 2006|
|12X1||BRSE (Berne Stock Exchange)||Yes||Common Shares||CH||CHF||Apr 2006|
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system diseases. The company’s lead drug candidate is ANAVEX 2-73, which is in Phase III clinical trial for the treatment of Alzheimer’s disease; Phase II clinical trials to treat Parkinson’s disease; and preclinical clinical trials to treat Rett syndrome, epilepsy, infantile spasms, Fragile X syndrome, Angelman syndrome, multiple sclerosis, and tuberous sclerosis complex. Its preclinical drug candidates include ANAVEX 3-71, a central nervous system (CNS)-penetrable mono-therapy to treat Alzheimer’s and Parkinson’s diseases; ANAVEX 1-41, a sigma-1 agonist for the treatment of depression, stroke, Parkinson’s, and Alzheimer’s diseases; ANAVEX 1066, a mixed sigma-1/sigma-2 ligand for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company is based in New York, New York.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/04/05 02:45|
|End of Day Share Price||2020/04/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.